Ikena Oncology, Inc. announced discontinuation of the clinical IK-930 program, the company?s TEAD1- selective Hippo pathway inhibitor and continued clinical development of IK-595, a novel MEK-RAF molecular glue. Concurrently, Ikena is evaluating strategic options for both the Company and its development pipeline. Pipeline & Corporate Updates IK-930: TEAD1-Selective Hippo Pathway Inhibitor: Based on a review of clinical data to date, available resources, and the company?s strategic priorities, the Company decided to discontinue development of IK-930; The IK-930 Phase 1 program will begin winddown activities; treatment will continue for patients enrolled to date who have derived benefit; The company will seek strategic options for the program, including potential partners for development of IK-930 in combination with other targeted agents.

IK-595: MEK-RAF Molecular Glue: The first two cohorts in the Phase 1 study of IK-595 in patients with RAS and RAF mutant cancers have cleared; backfilling in select cohorts is planned for the second half of 2024; Promising early pharmacokinetics (PK) and pharmacodynamics (PD) activity has been observed, with dose dependent exposure and target modulation measured in the blood; Reached above 80% pERK inhibition at 4 hours post dosing to date, with above 60% inhibition sustained through 24 hours; dose escalation continues.